Evidence map›Paper›PMID 37758962›Full record

SynthesisJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2023

Comparison of cardiac magnetic resonance imaging and fluorodeoxyglucose positron emission tomography in the assessment of myocardial viability: meta-analysis and systematic review.

Mehul Adhaduk, Bishow Paudel, Kan Liu, Mahi Ashwath, Milena A Gebska, Kimberly Delcour, Riley J Samuelson, Michael Giudici

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Diagnostics (Basel, Switzerland) · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mehul AdhadukDivision of General Internal Medicine, Department of Internal Medicine, University of Iowa, Iowa City, USA. mehul-adhaduk@uiowa.edu.
Bishow PaudelDivision of General Internal Medicine, Department of Internal Medicine, University of Iowa, Iowa City, USA.
Kan LiuDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa, Iowa City, USA.
Mahi AshwathDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa, Iowa City, USA.
Milena A GebskaDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa, Iowa City, USA.
Kimberly DelcourDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa, Iowa City, USA.
Riley J SamuelsonUniversity of Iowa Libraries, University of Iowa, Iowa City, USA.
Michael GiudiciDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa, Iowa City, USA.
University of Iowa · USState Library of Iowa · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimContrast-enhanced cardiac magnetic resonance (Ce-CMR) and Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) are frequently utilized in clinical practice to assess myocardial viability. However, studies evaluating direct comparison between Ce-CMR and FDG-PET have a smaller sample size, and no clear distinction between the two imaging modalities has been defined. To address this gap, we conducted a meta-analysis of studies comparing Ce-CMR and FDG-PET for the assessment of myocardial viability.

methodsWe searched PubMed, EMBASE, Scopus, and Web of Science databases from their inception to 4/20/2022 with search terms "viability" AND "heart diseases" AND "cardiac magnetic resonance imaging" AND "positron-emission tomography." We extracted patient characteristics, segment level viability assessment according to Ce-CMR and FDG-PET, and change in regional wall motion abnormalities (RWMA) at follow-up.

resultsWe included four studies in the meta-analysis which provided viability assessment with Ce-CMR and FDG-PET in all patients and change in RWMA at follow-up. There were 82 patients among the four included studies, and 585 segments were compared for viability assessment. There were 59 (72%) males, and mean age was 65 years. The sensitivity (95% confidence interval-CI) and specificity (CI) of Ce-CMR for predicting myocardial recovery were 0.88 (0.66-0.96) and 0.64 (0.49-0.77), respectively. The sensitivity (CI) and specificity (CI) of FDG-PET for predicting myocardial recovery were 0.91 (0.63-0.99) and 0.67 (0.49-0.81), respectively.

conclusionFDG-PET and Ce-CMR have comparable diagnostic parameters in myocardial viability assessment and are consistent with prior research.

Indexed as

Fluorodeoxyglucose F18Tomography, X-Ray ComputedAgedFemaleHeartHumansMagnetic Resonance ImagingMalePositron-Emission TomographyRadiopharmaceuticalsSensitivity and SpecificityFluorodeoxyglucose F18Radiopharmaceuticalsdiagnostic and prognostic applicationmeta-analysisMRIMyocardial ischemia and infarctionPETviability

Identifiers

PMID37758962
OpenAlexW4387081248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.